ENETS Abstract Search
Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue
Introduction: Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.
Aim(s): Evaluated the occurrence of PEI in patients with advanced NENs treated with SSA
Materials and methods: An unicentric, observational, prospective study has been designed. Enrolled a continuous series of pts with advanced GI NENs tumours treated with SSA LAR. In order to evaluate the presence of EPI, the following blood tests were performed: FE-1 dosage, Vitamin D, PTH, HbA1C, Glycaemia, Serum Calcium, Total cholesterol and triglycerides. The FE-1 values were considered positive with <200 μg / g or U / L
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Rinzivillo M
Keywords: Pancreatic Exocrine Insufficiency,
To read the full abstract, please log into your ENETS Member account.